These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37656263)

  • 21. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
    Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
    Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
    Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
    Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
    Badin F
    Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 25. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer.
    Kepp O; Zitvogel L; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1795995. PubMed ID: 32923159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.
    Azar I; Yazdanpanah O; Jang H; Austin A; Kim S; Chi J; Alkassis S; Saha BK; Chopra A; Neu K; Mehdi S; Mamdani H
    JAMA Netw Open; 2022 Oct; 5(10):e2237699. PubMed ID: 36264573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lurbinectedin in small cell lung cancer.
    Manzo A; Sforza V; Carillio G; Palumbo G; Montanino A; Sandomenico C; Costanzo R; Esposito G; Laudato F; Mercadante E; La Manna C; Muto P; Totaro G; De Cecio R; Picone C; Piccirillo MC; Pascarella G; Normanno N; Morabito A
    Front Oncol; 2022; 12():932105. PubMed ID: 36110944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De Novo and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways.
    Chakraborty S; Coleman C; Manoj P; Demircioglu D; Shah N; de Stanchina E; Rudin CM; Hasson D; Sen T
    Clin Cancer Res; 2023 Sep; 29(17):3526-3540. PubMed ID: 37382635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
    Leary A; Oaknin A; Trigo JM; Moreno V; Delord JP; Boni V; Braña I; Fernández C; Kahatt C; Nieto A; Cullell-Young M; Zeaiter A; Subbiah V
    Eur J Cancer; 2023 Oct; 192():113259. PubMed ID: 37634282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
    Farago AF; Drapkin BJ; Lopez-Vilarino de Ramos JA; Galmarini CM; Núñez R; Kahatt C; Paz-Ares L
    Future Oncol; 2019 Jan; 15(3):231-239. PubMed ID: 30362375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 32. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
    Aviles P; Altares R; van Andel L; Lubomirov R; Fudio S; Rosing H; Márquez Del Pino FM; Tibben MM; Benedit G; Nan-Offeringa L; Luepke Estefan XE; Francesch A; Zeaiter A; Cuevas C; Schellens JHM; Beijnen JH
    Drug Metab Dispos; 2022 Apr; 50(4):327-340. PubMed ID: 35042701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
    Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
    Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
    Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
    J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.
    Sands J; Subramanian J
    Front Oncol; 2023; 13():1161931. PubMed ID: 38221913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
    Mark M; Rusakiewicz S; Früh M; Hayoz S; Grosso F; Pless M; Zucali P; Ceresoli GL; Maconi A; Schneider M; Froesch P; Tarussio D; Benedetti F; Dagher J; Kandalaft L; von Moos R; Tissot-Renaud S; Schmid S; Metaxas Y
    ESMO Open; 2022 Jun; 7(3):100446. PubMed ID: 35427834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
    Amarasena IU; Chatterjee S; Walters JA; Wood-Baker R; Fong KM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006849. PubMed ID: 26233609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.